MDL-17,043, a new drug combining positive inotropic and peripheral vasodilatory properties, was found to be effective in treatment of congestive heart failure. It is available in intravenous as well as oral forms. Until its introduction, the overall hemodynamic effects of MDL-17,043 could have been achieved only with a combination of conventional agents. It therefore simplifies therapy in congestive heart failure and may improve elderly patients’ compliance. Since the mechanism of the positive inotropic effect of MDL-17,043 differs from those of digitalis glycosides and sympathomimetic amines, it is possible that unlike these agents the effect of MDL-17,043 will not decline with age.
KeywordsCardiomyopathy Cardiol Glycoside Digoxin Captopril
Unable to display preview. Download preview PDF.
- 2.Roebel LE, et al: Selective inotropic activity of RMI-17,043 in anesthetized and conscious dogs. Fed Proc 41:1310, 1982.Google Scholar
- 3.Investigational Brochure RMI 17,043, Merrell-Dow Research Center, Merrell Dow Pharmaceuticals Inc, Cincinnati, Ohio, 1981.Google Scholar
- 6.Kereiakes DJ, et al: Mechanisms of improved left ventricular function with MDL-17,043 in heart failure [abstr]. Circulation 68:III–373, 1983.Google Scholar
- 7.Amin D, et al: Comparative hemodynamic effects of dobutamine and MDL 17,043 in congestive heart failure [abstr]. Circulation 68:III–120, 1983.Google Scholar